Investment
Features
FeesSafety
Academy
More
Pluang+

Dogecoin drops 59.1% in a year, raising tax questions for U.S. investors on gains and losses

Market News
20 Oct 2026
Tokenpost
View Source
Bearish
Dogecoin drops 59.1% in a year, raising tax questions for U.S. investors on gains and losses

Dogecoin (DOGE) fell 59.1% over the past 12 months as of October 20, prompting U.S. investors to consider tax implications on any realized gains or losses. The price decline affects how gains or losses are calculated, depending on the purchase date, holding period, and sale proceeds. Short-term gains apply to coins held one year or less, while long-term gains apply to those held longer. Investors must track acquisition dates and costs to determine taxable results, as losses on personal-use DOGE are not deductible but investment losses can offset gains or reduce taxable income up to certain limits.

Dogecoin's 59.1% price drop over the past year sets a backdrop for tax considerations in the U.S. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 21, 2026 03:41 WIB: out of 50 major cryptocurrencies priced on Pluang, 45 rose and 4 fell today. Notable movers include XTZ (Tezos) at Rp5.654 with a 1-day change of +4.65% and Pluang order activity showing 67% Sell / 33% Buy, BAT (Basic Attention Token) at Rp3.601 with +4.63% and 84% Sell / 16% Buy, and GRT (The Graph) at Rp446 with +4.43% and 94% Sell / 6% Buy. Typical hold times range from 93 to 101 days for these tokens.

More News

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...

Company Fundamentals
Neutral
47 minutes ago
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...

Analyst Insights
Bullish
1 hour ago
Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...

Company Fundamentals
Bearish
1 hour ago
CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...

Others
Neutral
1 hour ago
Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App